SBT 11 5301
Alternative Names: SBT-11-5301; SBT-115301 - Sonoma BiotherapeuticsLatest Information Update: 28 Aug 2025
At a glance
- Originator Sonoma Biotherapeutics
- Class Anti-inflammatories; Antihyperglycaemics; Recombinant fusion proteins
- Mechanism of Action T lymphocyte inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Type 1 diabetes mellitus
Most Recent Events
- 28 Aug 2025 No recent reports of development identified for phase-I development in Type-1 diabetes mellitus(In volunteers) in USA (IM)
- 28 Aug 2025 No recent reports of development identified for phase-I development in Type-1 diabetes mellitus(In volunteers) in USA (IV)
- 03 Jan 2024 Sonoma Biotherapeutics completes a phase I trial in Type 1 diabetes mellitus (In volunteers) in USA (IV) (IM)(NCT05388981)